Two Different Questions, Two Different Sets of Records
When a patient sends a file to a hospital in China, the first instinct is often to gather everything and send it all. That is understandable, but it blurs two questions that need different evidence. The first question is historical: what is this cancer, what stage was it at diagnosis, and what treatments have already been given. The second question is forward-looking: is immunotherapy a reasonable option now, and can it actually be delivered in the setting the patient is considering.
Old records are strongest for the first question. A pathology report identifies the tumour type. Imaging shows where disease was seen at a point in time. Treatment summaries show which drugs were used, at what dose, and how the patient responded. These documents do not expire in the sense of becoming irrelevant, but they describe a patient who existed at that moment. If the last scan was months ago, it cannot tell a clinician what is happening today.
A new assessment is not simply a repeat of the old one. It asks whether the current situation still matches the assumptions in the old file, and whether anything has changed that would alter the recommendation. That might mean new imaging, new blood work, or a fresh biopsy. It might also mean none of those, if the existing records are recent and complete. The point is that the decision about what to add belongs to the treating clinician, not to a checklist applied in advance.
This distinction matters for planning. A patient who assumes the old file is enough may arrive expecting a treatment decision, only to find that the hospital wants current staging first. A patient who assumes everything must be repeated may spend money and time on tests that add nothing. The useful middle ground is to ask the receiving team what the old records already answer and what specific gap they need filled.
What Tumour Type and Biomarkers Actually Determine
Immunotherapy is not a single treatment. It describes a group of approaches that help the immune system act against cancer, and whether any of them is appropriate depends on the cancer and the individual assessment. A therapy that is standard for one tumour type may have no role in another. Even within the same cancer type, the presence or absence of certain biomarkers can change whether a particular immunotherapy is considered at all.
This is why the pathology report and any molecular testing matter so much. They are not administrative paperwork; they are the evidence that determines whether a treatment is even in the conversation. If a biomarker result is missing, the receiving clinician may need to know whether it was never tested, tested and negative, or tested at a different laboratory with a different method. Those are different situations, and they lead to different next steps.
Previous treatment history matters in a similar way. Some immunotherapies are used as first-line treatment, others after other therapies have been tried. A clinician reviewing the file needs to know not only which drugs were given, but in what sequence and with what result. A summary that says only 'chemotherapy' is far less useful than one that lists the agents, the dates, and the response.
For an overseas patient, the practical implication is that the quality of the old records directly affects the usefulness of any preliminary opinion. A records-based review can identify what is missing and what questions to ask. It cannot substitute for the treating team's own assessment of whether a specific immunotherapy is appropriate for this patient.
Why a Preliminary Review Is Not a Treatment Decision
A common misunderstanding is that sending records to China and receiving a reply means a treatment has been agreed. It does not. A preliminary review can look at the available diagnosis, the records, and the patient's main question. It can identify missing information and suggest a relevant next step. It is not a diagnosis, and it is not a promise of acceptance.
The distinction is not bureaucratic caution. Immunotherapy decisions depend on details that a remote reviewer may not have: the patient's current performance status, organ function, concurrent medications, autoimmune history, and the treating team's own examination. A file can suggest that a treatment is worth discussing. It cannot confirm that the patient is a suitable candidate, and it cannot confirm that the hospital will offer it.
This matters for how a patient interprets any reply. If a coordinator says the case looks relevant to a specialist, that means the records are worth a clinician's time. It does not mean the clinician has agreed to treat. If a specialist replies with questions, that is not a rejection; it is the normal process of narrowing a decision that cannot be made from documents alone.
The practical action is to treat any preliminary reply as a set of questions to bring to the treating team, not as a conclusion. Ask what remains uncertain, what the clinician would need to see in person, and what alternatives would be considered if immunotherapy is not appropriate.
Availability Is a Separate Question From Suitability
Even when immunotherapy is clinically appropriate, a second question remains: is the specific treatment available in the setting the patient is considering, and under what conditions. These are not the same question, and conflating them leads to false expectations in both directions.
Availability can depend on the hospital's formulary, the drug's regulatory status, whether the patient would be treated within a clinical trial, and whether the hospital accepts international patients for that particular service. None of these can be assumed from the fact that a drug exists somewhere in the world or is approved in another country. Foreign approval does not establish Chinese availability, and a hospital's general reputation in oncology does not establish that it offers every immunotherapy.
This is why the useful question is not 'does China have immunotherapy' but 'for my diagnosis, at this hospital, is this specific treatment available, and what would need to be confirmed first'. That question has a concrete answer that a hospital can give, and it is worth asking in writing before making travel plans.
It is also worth asking how monitoring would continue. Some immunotherapies require regular assessment during treatment, and a patient planning to return home needs to know what follow-up would look like, who would provide it, and what records would travel back with them. These are practical questions that belong in the same conversation as the treatment decision, not after it.
What to Send, and What to Ask Before Sending It
The most useful first step is not a complete medical archive. It is a short summary that lets a coordinator or clinician understand the case and identify what is missing. That summary should include the diagnosis, the date it was confirmed, the treatments already given, the most recent imaging or assessment, and the patient's main question.
From there, the specific documents that matter can be requested. Pathology reports, molecular or biomarker results, treatment summaries, and recent imaging reports are typically the items a clinician would want to see. The patient does not need to guess the full list in advance; asking what the receiving team needs is part of the process.
It is also reasonable to ask what the old records already answer. If a recent scan and a complete treatment history are available, a clinician may be able to form a view without new tests. If the records are old or incomplete, the clinician may want current staging before commenting. Either way, the answer is specific to the case, and asking avoids both unnecessary repetition and unnecessary delay.
One boundary is worth stating plainly: an initial enquiry does not require buying a proxy consultation. A patient can start with a short summary and a question. If a records-based specialist opinion is useful later, that is a separate decision with its own scope and fee, and it should be discussed before anything is purchased.
The Next Practical Step
The decision this article addresses is narrow: what an old record answers versus what a new assessment adds. The answer is that old records establish the history and the tumour characteristics, while a new assessment asks whether immunotherapy is appropriate now and whether it can be delivered in the setting the patient is considering. Neither replaces the other, and neither can be settled by a remote review alone.
For a patient considering care in China, the useful next step is to prepare a short summary rather than a full archive, state the main question clearly, and ask what the receiving team would need to see. That enquiry is free, and it does not commit the patient to any service. If the case looks relevant to a specialist, the next conversation can address the specific treatment, its availability, and how monitoring would continue at home.
It is also worth keeping local care in view. If symptoms are worsening, that takes priority over an overseas enquiry. Immunotherapy is a treatment decision that belongs to the treating clinician and the patient, and the role of any coordination service is to help that conversation happen with the right records in front of the right people.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.